Clinical Scorecard: Evaluation of the Safety and Effectiveness of an Extended Macular Vision Intraocular Lens (IOL) for Age-Related Macular Degeneration (AMD) in Everyday Clinical Practice

At a Glance

Key Highlights

• AMD is the leading cause of legal blindness, affecting millions worldwide.
• The EyeMax Mono IOL is designed to improve visual outcomes for AMD patients.
• Study evaluates safety and efficacy using real-world evidence from multiple centers.
• Implantation of EyeMax Mono IOL can enhance visual function despite underlying retinal disease.
• Surgical intervention aims for emmetropia or modest hypermetropia based on AMD severity.

Guideline-Based Recommendations

Diagnosis

• Categorize AMD severity into early, intermediate, and late using fundus photography and OCT.

Management

• Consider EyeMax Mono IOL for AMD patients with concurrent cataracts.

Monitoring & Follow-up

• Assess intraoperative and postoperative complications, visual acuity changes, and intraocular pressure.

Risks

• Inform patients about the limitations of IOL implantation in preventing retinal disease progression.

Patient & Prescribing Data

Patients with AMD and cataracts, with healthy retina within 10° from the fovea.

EyeMax Mono IOL provides a larger retinal area of focus compared to standard IOLs.

Clinical Best Practices

• Ensure informed consent regarding the limited benefits of IOL in extensive macular disease.
• Utilize wavefront-optimized optics for better image quality across the macula.
• Monitor visual acuity using standardized charts for accurate assessment.

Related Resources & Content

• Study on AMD prevalence
• EyeMax Mono IOL specifications
• Visual acuity measurement methods